Revance Therapeutics (RVNC) Reports In-Line Q2 EPS, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
William Blair Downgrades Revance Therapeutic (RVNC) to Market Perform
August 12, 2024 11:12 AM EDTWilliam Blair analyst Tim Lugo downgraded Revance Therapeutic (NASDAQ: RVNC) from Outperform to Market Perform.
The analyst comments "Before the market open on Monday, August 12, Revance announced Crown Laboratories, a privately held, global leader in the skincare industry, will commence and... More
Stifel Downgrades Revance Therapeutic (RVNC) to Hold Following Go Private Deal
August 12, 2024 10:07 AM EDTStifel analyst Annabel Samimy downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Hold with a price target of $6.66 (from $20.00).
The analyst comments "Surprising to us, RVNC announced this morning its intention to merge with Crown Laboratories, a privately-held, global skincare company for... More
